- Building a sustainable global supply operation for the future while navigating increased complexity, including growth in products and modalities and evolving needs of patients
- Focusing on expanding production capacity, enhancing operational efficiency, and accelerating the development and delivery of life-saving medicines and vaccines
- Exploring and implementing new manufacturing technologies such as continuous manufacturing, advanced analytics, and automation to streamline production processes and improve product quality and consistency
- Decarbonizing supply chains while ensuring they remain resilient and agile for a healthier society for patients and society
—
Per Alfredsson
SVP, Global Biologics Operations AstraZeneca and President AstraZeneca AB
AstraZeneca
As Senior Vice President, Global Biologics Operations, Per leads the global biologics operations network, which includes five internal manufacturing sites across four countries, as well as the external biologics supply network. Since April 2020, Per has also served as co-lead for the COVID-19 vaccine program, AZD1222, during which he has led the rapid establishment and start-up of a complex manufacturing network of more than 20 partners across more than 15 countries.
Throughout his 24 years within AstraZeneca, Per has significant global experience across all aspects of manufacturing and supply having worked at sites in the UK, US and Sweden. Prior to assuming his current role in 2019, he successfully led Europe, Middle East and Africa (EMEA) Supply through a period of change during which the region strengthened its focus on manufacturing excellence and people development. He previously served in executive-level positions leading Global Supply Chain & Strategy, Sweden Operations and iPR Pharmaceuticals. Per holds a master’s degree in Chemical Engineering from the Royal Institute of Technology in Stockholm, Sweden.
